What is known and objective: Hyperthermia is an effective treatment modality that augments the anticancer effects of radiotherapy and chemotherapy. Hyperthermia-chemo-radiotherapy (HCRT) is a combination therapy that can strengthen anticancer effects through a synergistic interaction between heat, chemotherapy and radiation. Here, we carried out a systematic review and meta-analysis to evaluate the clinical efficacy and safety of chemoradiation combined with regional hyperthermia (HCRT) for oesophageal carcinoma. Methods: We conducted computer searches of foreign databases, including Cochrane Library, PubMed, EMBASE, Web of Science and Chinese databases, including CBM, CNKI and WanFang; we also retrieved other sources as supplement. All relevant randomized controlled trials (RCTs) were collected to compare HCRT and other therapies, including chemotherapy combined with radiotherapy (CRT) and radiotherapy alone (RT). After literature screening, data extraction and quality evaluation performed by appropriate criteria, the meta-analyses were conducted using RevMan 5.1 software (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). Results and discussion: Nineteen RCTs were included, comprising 1519 patients. Meta-analysis showed that the 1-, 3-, 5-and 7-year survival, complete response and total effective rates of the HCRT group were higher than those of the CRT group; the rates of gastrointestinal reaction, leucocytopenia and radiation oesophagitis in the HCRT group were lower than those of the CRT group, indicating significant differences (P < 0Á05). The 1-, 2-, 3-and 5-year survival, complete response and total effective rates of the HCRT group were higher than those of the RT group, the recurrence and distant metastasis rates of the HCRT group were lower than those of the RT group, and there were significant differences in all of the indicators (P < 0Á05). What is new and conclusions: This is the first systematic review and meta-analysis to evaluate HCRT for oesophageal carcinoma. Compared with CRT or RT, HCRT can improve long-term and short-term curative effects; it is also safe and feasible. Additional high-quality and large sample size RCTs will be necessary to further demonstrate the long-term survival benefits and comprehensive safety profile of HCRT.
WHAT IS KNOWN AND OBJECTIVE
Oesophageal cancer is a common malignant neoplasm of the digestive system, occurring in the oesophageal epithelial tissue. It is most prevalent in developing countries. An estimated 455 800 new cases of oesophageal cancer and 400 200 deaths occurred worldwide in 2012. The incidence rates vary internationally by more than 21-fold, with the highest rates found in eastern Asia and in eastern and southern Africa, and the lowest rates observed in western Africa. 1 The highest risk area, which extends from northern Iran through the central Asian republics to north-central China, is often referred to as the 'oesophageal cancer belt'. 2, 3 Traditional management of patients with oesophageal cancer has included surgical resection, radiotherapy and chemotherapy. However, survival rates remain poor, and many patients experience recurrence or develop metastatic disease soon after the use of these strategies, some of which are associated with serious complications. Various strategies have been proposed to improve the curative effect and reduce adverse reactions. Hyperthermia is a therapeutic procedure used to raise the temperature of a region of the body affected by cancer; it has proven to be a potent sensitizer of radiotherapy or chemotherapy. 4 In comprehensive treatment strategies, hyperthermia is generally utilized in combination with radiotherapy or chemotherapy.
The use of hyperthermia in the treatment of tumours has grown rapidly in clinical practice. A review confirmed the value of hyperthermia in the treatment of many tumour types. 4 Questions remain regarding the clinical value of combined hyperthermiachemo-radiotherapy (HCRT) for patients with oesophageal cancer. Although many relevant clinical studies have been conducted, the existing randomized controlled trials (RCTs) are limited by small sample size and inconclusive results. Therefore, we performed this meta-analysis of RCTs to assess the effectiveness and safety of combined HCRT in the treatment of oesophageal cancer and to provide a reference for further clinical practice and study.
METHODS

Study selection criteria
The studies were selected for review if they fulfilled the following inclusion criteria: (i) patients with histologically diagnosed primary oesophageal cancer; (ii) trials assessing the efficacy and safety of HCRT compared with chemo-radiotherapy (CRT) or radiotherapy (RT); and (iii) RCTs, regardless of the use of blinding.
When multiple publications from the same institution were identified as duplicates, only the most recent update with the largest number of patients or the longer follow-up period was included.
Literature search strategy
An electronic literature search was independently performed by two investigators (Yue Hu and Zheng Li), who searched the Cochrane Library, PubMed, EMBASE, Web of Science and Chinese literature databases (CBM, CNKI and WanFang). The search terms included oesophageal cancer, hyperthermia, chemotherapy, radiotherapy and randomized controlled trial. All searches used a topic search combined with a non-topic search. The search strategy had no language restrictions, and the search period was from the inception of the databases to 31 December 2015. All relevant RCTs were collected to evaluate the effectiveness and safety of HCRT for patients with oesophageal cancer. The reference lists of the identified articles were reviewed to identify additional potentially relevant studies. We also used Google Scholar to search for relevant papers. Both published and unpublished trials were sought to limit publication bias. We communicated with experts to determine whether they were aware of relevant unpublished trials relevant to this meta-analysis.
Literature screening
Studies were selected based on the inclusion and exclusion criteria. The title and abstract were analysed, and, if potentially relevant, the publication was then retrieved for analysis of the full text. If necessary, we contacted authors for missing data. All steps were independently completed by two investigators (Yue Hu and Zheng Li), and all steps were cross-checked. Discrepancies between the two investigators were resolved by discussion and consensus with a senior investigator (Yan Qu) . The final results were reviewed by all three investigators to avoid bias.
Data extraction and quality assessment
Two investigators (Yue Hu and Zheng Li) independently read each included article and performed data extraction, including study design, year of publication, number of patients, methodology, quality criteria and treatment outcomes. All data were extracted from the articles' text, tables and figures.
The quality of the studies was assessed using the following criteria: (i) the method of randomization; (ii) whether there was proper concealment of allocation; (iii) whether the groups were similar at baseline in terms of prognostic features; (iv) whether blinding existed; and (v) the results of follow-up. When a study did not report sufficient information to fulfil the above-mentioned assessment criteria, we attempted to obtain additional data directly from the paper's authors.
Statistical analysis
Data were synthesized using RevMan 5Á1 provided by the Cochrane organization. The heterogeneity between the results of the included research was determined using chi-square tests. The I 2 value was used to estimate the percentage of total variation across studies.
When the homogeneity of statistics between studies was considered adequate (P > 0Á1, I
2 < 50%), we used the fixed effects model to perform the meta-analysis; if there was obvious heterogeneity between the studies (P < 0Á1, I
2 > 50%), we analysed the sources of heterogeneity and then performed subgroup analyses according to the factors responsible for the heterogeneity. If there was statistical heterogeneity but no clinical and methodological heterogeneity, we used the random effects model to synthesize the data from the studies. If the heterogeneity was substantial between the included studies, we used qualitative synthetic analyses. We performed sensitivity analysis to assess the stability of the results when necessary.
The primary end point of this meta-analysis was overall survival (OS), defined as the time from random assignment to the last follow-up or death. Secondary end points were long-term effects including recurrence and distant metastasis rates, and short-term effects such as complete response rate and total effective rate. Safety was also assessed. 19 RCTs were included finally for meta-analysis, with a total of 1519 patients involved 
RESULTS
Results of the search and study identification
A total of 651 references were identified by comprehensive searches. Eighty-four articles were excluded as duplicates by EndNote, and 14 articles were excluded as duplicates by reviewers. The titles and abstracts of 553 potentially appropriate studies were read by the reviewers; 471 of these were excluded because they did not meet the inclusion criteria. Eighty-two studies were evaluated by full text to confirm their appropriateness for inclusion. In the end, a total of 19 RCTs met our eligibility criteria and were included in the meta-analysis. The 19 RCTs comprised a total sample of 1519 patients ( Fig. 1) .
Some significant papers were excluded to ensure the consistency and quality of the meta-analysis. For example, one RCT 5 was excluded for its intervention (chemotherapy combined with hyperthermia) and comparison (chemotherapy alone), which were incongruent with the inclusion criteria. Eleven significant papers [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] were excluded for their non-randomized or non-controlled design, or for data that were duplicated in the included studies.
Characteristics and quality of the included studies
In these 19 studies, 1519 patients were randomly assigned into HCRT, CRT and RT groups. The age, sex and clinical stage of patients were balanced between the experimental and control groups, with good baseline comparability and no statistically significant differences. Although there were some differences in terms of interventions, this was irrelevant to our analysis because the factors of non-hyperthermia or non-hyperthermo-chemotherapy were balanced in the two comparative groups of every study.
There was good agreement between the reviewers regarding the eligibility and quality of the studies. Table 1 illustrates the quality of all 19 RCTs included in the systematic review. An attempt was made to contact the corresponding authors of the RCTs when necessary to obtain missing details about methodological quality. The baseline features were similar between treatment arms in all 19 RCTs. The full details are listed in Table 1 .
Assessment of efficacy and safety
Results of HCRT vs. CRT. The meta-analysis comparing the HCRT and CRT groups showed that the 1-, 3-, 5-and 7-year survival rates of the HCRT group were better than those of the CRT group, which were all significantly different (P < 0Á05). The OR, 95% CI and P-values for the 1-, 3-, 5-and 7-year survival rates were [1Á79, (1Á12, 2Á84), HCRT, Hyperthermia-chemo-radiotherapy; CRT, chemo-radiotherapy; RT, radiotherapy alone; KPS, Karnofsky Performance Scale; VS, versus.
significant difference was found between HCRT and CRT with respect to the 2-year survival rate [OR = 1Á53, 95% CI = (0Á95, 2Á47), P = 0Á08] (Fig. 2 ). There were no statistically significant differences between HCRT and CRT groups with regard to the recurrence rate and distant metastasis rate (OR, 95% CI and P-values of [0Á59, (0Á33, 1Á06), P = 0Á08] for recurrence and [0Á83, (0Á46, 1Á48), P = 0Á52] for distant metastasis). Compared with CRT, HCRT was significantly superior in terms of complete response and total effective rates (OR, 95% CI and P-values of [2Á00, (1Á49, 2Á69), P < 0Á00001] for complete response and [3Á47, (2Á46, 4Á89), P < 0Á00001] for total effectiveness) ( Table 2) . Some significant safety benefits were observed with HCRT in terms of gastrointestinal reaction, leucocytopenia and radiation oesophagitis; these were all significantly different (P < 0Á05), with OR, 95% CI and P-values of [0Á43, (0Á30, 0Á61), P < 0Á00001], [0Á49, (0Á35, 0Á68), P < 0Á0001], [0Á43, (0Á31, 0Á60), P < 0Á00001], respectively. No significant difference was found between HCRT and CRT with respect to the incidence of radiation pneumonitis [OR = 0Á77, 95% CI = (0Á48, 1Á23), P = 0Á27] ( Table 2) .
Results of HCRT vs. RT. The meta-analysis comparing the HCRT and RT groups showed that compared with RT, a significant survival advantage was observed with HCRT at 1 year [OR = 3Á20, 95% CI = (2Á07, 4Á95), P < 0Á00001], 2 years [OR = 2Á09, 95% CI = (1Á13, 3Á85), P = 0Á02], 3 years [OR = 2Á43, 95% CI = (1Á67, 3Á51), P < 0Á00001] and 5 years [OR = 3Á47, 95% CI = (1Á08, 11Á17), P = 0Á04] (Figs 3 and 4) .
Compared with the RT group, the HCRT group had significantly lower recurrence and distant metastasis rates (OR, 95% CI and Pvalues: [0Á39, (0Á24, 0Á64), P = 0Á0001] and [0Á46, (0Á28, 0Á77), P = 0Á003], respectively) and significantly higher complete response and total effective rates (OR, 95% CI and P-values: [2Á12, (1Á29, 3Á47), P = 0Á003] and [4Á18, (1Á68, 10Á43), P = 0Á002], respectively) ( Table 3) .
Compared with the RT group, the HCRT group presented a trend of higher rates in gastrointestinal reaction, leucocytopenia and radiation oesophagitis and a trend of lower rates in radiation pneumonitis; however, none of the differences were statistically significant (P > 0Á05) ( Table 3) .
DISCUSSION
Carcinoma of the oesophagus is an aggressive and lethal malignancy with an increasing incidence worldwide, 36 and the rising incidence is mainly due to oesophageal adenocarcinoma. 37, 38 Patients with oesophageal cancer have a poor prognosis because they often have no symptoms until their disease is advanced. Screening recommendations are lacking unless patients have Barrett's oesophagitis. Often, oesophageal cancer is not diagnosed until patients present with dysphagia, odynophagia, anaemia or weight loss. When symptoms occur, the disease is often in stage III or beyond. 39 Surgery alone remains the international standard of care for sufficient early stage disease. The treatment of patients with advanced oesophageal cancer is more complex and remains controversial. Although there is marked geographical variation in standard practice, there is an international consensus that multimodality therapy is appropriate for advanced stage disease. 36, 39, 40 Radiotherapy combined with chemotherapy enhances antitumour effects by synergistically damaging cancer cells. Chemotherapy theoretically also reduces the risk of distant metastatic disease by the eradication of micrometastases. A Radiation Therapy Oncology Group study demonstrated a survival benefit with the addition of platinum-based chemotherapy to radiation compared with radiation alone for patients with non-surgical oesophageal cancer. 41, 42 The worldwide interest in hyperthermia began with the first Hyperthermia is an effective treatment modality that augments the anticancer effects of radiotherapy and chemotherapy. The significant beneficial effects of hyperthermia when added to radiotherapy have been demonstrated by many clinical trials, [47] [48] [49] [50] as have the benefits of chemotherapy combined with hyperthermia.
5,10,13,51-53 Hyperthermia-chemo-radiotherapy (HCRT) is a combination therapy that can strengthen anticancer effects through a synergistic interaction between heat, chemotherapy and radiation. 6, 9, 12, 15, 44, [54] [55] [56] [57] [58] Thus, theoretically, HCRT should be superior to chemoradiation or any single therapy, a concept that has been validated in clinical researches of different tumour types. 7, 8, 14, 58, 59 HCRT, Hyperthermia-chemo-radiotherapy; CRT, chemo-radiotherapy; OR, odds ratio; CI, confidence interval.
Several clinical trials of HCRT for oesophageal cancer have been reported, but most of them have been underpowered because of their limited sample size and methodological quality. Therefore, we performed this meta-analysis of RCTs to assess the effectiveness and safety of HCRT in the treatment of oesophageal cancer. The results indicate that compared with CRT or RT, HCRT can significantly improve long-term survival and short-term effect while also being both safe and feasible. Hyperthermia may allow reductions in the dose of radiotherapy or chemotherapy while achieving the same treatment outcomes, suggesting the potential of hyperthermia to improve clinical safety. This is the reason, compared with CRT, significant safety improvements were observed with HCRT in terms of gastrointestinal reaction, leucocytopenia and radiation oesophagitis.
There was some difference in the stage of oesophageal cancer among the included studies. Furthermore, intervention had some variation. For example, chemotherapy was administered differently in some studies, and, in others, some patients underwent surgical resection following previous treatment. These differences were irrelevant for the purposes of this meta-analysis because the baseline and treatment were balanced between the two arms in each study, despite the variation among the different studies. This concept has been endorsed by many published meta-analyses. [60] [61] [62] [63] [64] We can infer that compared with CRT or RT, HCRT is more useful in both the neoadjuvant and adjuvant settings for patients with oesophageal cancer. Furthermore, in patients who are not surgical candidates, HCRT can be used as definitive treatment.
Some interesting characteristics of hyperthermia may be associated with the significant improvement in long-term survival rate. 11, 65 Hyperthermia exerts a tumour-selective kill effect by a complex mechanism, an effect that was enhanced by its combination with radiotherapy or chemotherapy. 43, 66 Hyperthermia has also been proven to directly or indirectly modulate the cells of the innate and adaptive immune systems, thereby improving their effectiveness. [67] [68] [69] [70] [71] As a result, the addition of hyperthermia could be considered a personalized cancer treatment approach by specifically activating the immune system against an individual's unique tumour.
There have been some negative results, where hyperthermia treatment techniques were inadequate for patients. 43, 72 Only when physically optimal locoregional hyperthermia is achieved will its clinical potential be apparent. Non-invasive temperature measurement, targeted therapy and control of the thermal dose are key factors in hyperthermia treatment. Two studies 73, 74 suggested that targeted hyperthermia using nanoparticles is a promising strategy. Because HCRT results in a synergistic interaction between hyperthermia, chemotherapy and radiation, factors influencing the degree of these interactions should be further investigated.
Several potential limitations of this meta-analysis should be taken into consideration. First, some of the included RCTs did not report the detailed method of random sequence generation, and all trials except for one did not mention concealment of allocation. Blinding is not appropriate for physicians during the procedures. Moreover, the primary effects are all objective indicators that are independent of blinding. Therefore, the evaluation for the assessment of blinding is considered as low risk of bias. However, most of the included trials are not of good quality based on the criteria set. Second, recurrence, distant metastasis and safety were not reported in a standard manner throughout the trials. Thus, there may be some bias in the meta-analysis. Third, the outcome measures that did not achieve significant differences between HCRT and other groups were all associated with low numbers of patients by the few trials reported. As such, the negative outcomes might well be related to biases with insufficient sample size and therefore not enough power to detect the difference. In addition, none of the included studies reported the outcome measures with the classification of histologic types, such as adenocarcinoma and squamous cell carcinoma; therefore, we could not perform subgroup analyses by histologic types. For these reasons, we suggest that prospective trials should be well designed, well executed and well reported to adequately evaluate the role of HCRT for oesophageal cancer treatment. It will also be necessary to collect data from non-randomized studies to adequately assess the safety of HCRT.
WHAT IS NEW AND CONCLUSION
This is the first systematic review and meta-analysis to evaluate HCRT for oesophageal carcinoma. The results suggest that HCRT is an ideal treatment option for oesophageal cancer. Compared with CRT or RT, HCRT can significantly improve long-term survival and short-term effect while being safe and feasible. It is important to improve hyperthermia treatment techniques, and we anticipate that this treatment strategy will play an increasing role in clinical practice in the future. 
